{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,2]],"date-time":"2025-12-02T03:28:06Z","timestamp":1764646086063},"reference-count":46,"publisher":"Public Library of Science (PLoS)","issue":"5","license":[{"start":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T00:00:00Z","timestamp":1462320000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"The National Science Centre, Poland","award":["2011\/01\/B\/NZ4\/05796"],"award-info":[{"award-number":["2011\/01\/B\/NZ4\/05796"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0154520","type":"journal-article","created":{"date-parts":[[2016,5,4]],"date-time":"2016-05-04T18:09:10Z","timestamp":1462385350000},"page":"e0154520","update-policy":"http:\/\/dx.doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":2,"title":["Effects of Designer Hyper-Interleukin 11 (H11) on Hematopoiesis in Myelosuppressed Mice"],"prefix":"10.1371","volume":"11","author":[{"given":"Hanna","family":"Dams-Kozlowska","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eliza","family":"Kwiatkowska-Borowczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katarzyna","family":"Gryska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Lewandowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Marszalek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sebastian","family":"Adamczyk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anna","family":"Kowalik","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewa","family":"Leporowska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrzej","family":"Mackiewicz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2016,5,4]]},"reference":[{"issue":"4","key":"ref1","first-page":"282","article-title":"Managing thrombocytopenia associated with cancer chemotherapy","volume":"29","author":"DJ Kuter","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"4","key":"ref2","first-page":"297","article-title":"Thrombocytopenia: optimizing approaches in cancer patients","volume":"29","author":"C Piatek","year":"2015","journal-title":"Oncology (Williston Park)"},{"issue":"1","key":"ref3","doi-asserted-by":"crossref","first-page":"S26","DOI":"10.1053\/j.seminhematol.2008.12.007","article-title":"Management of chemotherapy-induced thrombocytopenia: current status of thrombopoietic agents","volume":"46","author":"S Vadhan-Raj","year":"2009","journal-title":"Semin Hematol"},{"issue":"6","key":"ref4","doi-asserted-by":"crossref","first-page":"381","DOI":"10.2165\/00044011-200727060-00002","article-title":"Economic burden of haematological adverse effects in cancer patients: a systematic review","volume":"27","author":"SY Liou","year":"2007","journal-title":"Clin Drug Investig"},{"issue":"17\u201318","key":"ref5","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.drudis.2008.06.002","article-title":"Emerging treatments for thrombocytopenia: increasing platelet production","volume":"13","author":"K Peeters","year":"2008","journal-title":"Drug Discov Today"},{"issue":"10","key":"ref6","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/blood.V100.10.3457","article-title":"Recombinant human thrombopoietin: basic biology and evaluation of clinical studies","volume":"100","author":"DJ Kuter","year":"2002","journal-title":"Blood"},{"issue":"7","key":"ref7","doi-asserted-by":"crossref","first-page":"2599","DOI":"10.1182\/blood.V99.7.2599","article-title":"Development of pancytopenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor","volume":"99","author":"RL Basser","year":"2002","journal-title":"Blood"},{"issue":"12","key":"ref8","doi-asserted-by":"crossref","first-page":"3241","DOI":"10.1182\/blood.V98.12.3241","article-title":"Thrombocytopenia caused by the development of antibodies to thrombopoietin","volume":"98","author":"J Li","year":"2001","journal-title":"Blood"},{"issue":"2","key":"ref9","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1111\/bjh.12781","article-title":"Milestones in understanding platelet production: a historical overview","volume":"165","author":"DJ Kuter","year":"2014","journal-title":"Br J Haematol"},{"issue":"Suppl 2","key":"ref10","doi-asserted-by":"crossref","first-page":"S63","DOI":"10.1016\/S0049-3848(14)50011-4","article-title":"Thrombocytopenia in cancer patients","volume":"133","author":"HA Liebman","year":"2014","journal-title":"Thromb Res"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1186\/1471-2407-13-121","article-title":"Results of a phase I dose escalation study of eltrombopag in patients with advanced soft tissue sarcoma receiving doxorubicin and ifosfamide","volume":"13","author":"SP Chawla","year":"2013","journal-title":"BMC Cancer"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/1756-8722-5-71","article-title":"A randomized, double-blind, placebo-controlled phase 2 study evaluating the efficacy and safety of romiplostim treatment of patients with low or intermediate-1 risk myelodysplastic syndrome receiving lenalidomide","volume":"5","author":"ES Wang","year":"2012","journal-title":"J Hematol Oncol"},{"issue":"3","key":"ref13","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.seminhematol.2007.04.005","article-title":"Cytokines for the treatment of thrombocytopenia","volume":"44","author":"SO Ciurea","year":"2007","journal-title":"Semin Hematol"},{"issue":"6","key":"ref14","doi-asserted-by":"crossref","first-page":"418","DOI":"10.2165\/00063030-199708060-00002","article-title":"Interleukin-11","volume":"8","author":"AJ Dorner","year":"1997","journal-title":"BioDrugs"},{"issue":"1","key":"ref15","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1080\/10428190600909115","article-title":"The role of interleukin-11 to prevent chemotherapy-induced thrombocytopenia in patients with solid tumors, lymphoma, acute myeloid leukemia and bone marrow failure syndromes","volume":"48","author":"M Bhatia","year":"2007","journal-title":"Leuk Lymphoma"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/1472-6750-12-8","article-title":"A designer hyper interleukin 11 (H11) is a biologically active cytokine","volume":"12","author":"H Dams-Kozlowska","year":"2012","journal-title":"BMC Biotechnol"},{"issue":"9","key":"ref17","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.7150\/ijms.5638","article-title":"Designer cytokine hyper interleukin 11 (H11) is a megakaryopoietic factor","volume":"10","author":"H Dams-Kozlowska","year":"2013","journal-title":"Int J Med Sci"},{"issue":"12","key":"ref18","doi-asserted-by":"crossref","first-page":"1555","DOI":"10.1517\/14712598.2011.627852","article-title":"Hyper-interleukin-11 novel designer molecular adjuvant targeting gp130 for whole cell cancer vaccines","volume":"11","author":"WM Suchorska","year":"2011","journal-title":"Expert Opin Biol Ther"},{"issue":"6","key":"ref19","first-page":"3275","article-title":"Cellular Vaccines Modified with Hyper IL6 or Hyper IL11 Combined with Docetaxel in an Orthotopic Prostate Cancer Model","volume":"35","author":"J Mackiewicz","year":"2015","journal-title":"Anticancer Res"},{"issue":"Pt 1","key":"ref20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1042\/bj20030407","article-title":"Principles of interleukin (IL)-6-type cytokine signalling and its regulation","volume":"374","author":"PC Heinrich","year":"2003","journal-title":"Biochem J"},{"issue":"8","key":"ref21","doi-asserted-by":"crossref","first-page":"513","DOI":"10.5483\/BMBRep.2010.43.8.513","article-title":"GP130 cytokines and bone remodelling in health and disease","volume":"43","author":"NA Sims","year":"2010","journal-title":"BMB Rep"},{"issue":"46","key":"ref22","doi-asserted-by":"crossref","first-page":"36197","DOI":"10.1074\/jbc.M004648200","article-title":"Interleukin-11 signals through the formation of a hexameric receptor complex","volume":"275","author":"VA Barton","year":"2000","journal-title":"J Biol Chem"},{"issue":"1","key":"ref23","doi-asserted-by":"crossref","first-page":"284","DOI":"10.4049\/jimmunol.157.1.284","article-title":"Complex of the soluble IL-11 receptor and IL-11 acts as IL-6-type cytokine in hepatic and nonhepatic cells","volume":"157","author":"H Baumann","year":"1996","journal-title":"J Immunol"},{"issue":"11","key":"ref24","doi-asserted-by":"crossref","first-page":"3897","DOI":"10.1182\/blood.V89.11.3897","article-title":"Interleukin-11: review of molecular, cell biology, and clinical use","volume":"89","author":"X Du","year":"1997","journal-title":"Blood"},{"issue":"6","key":"ref25","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1667\/0033-7587(2002)157[0642:AORHIA]2.0.CO;2","article-title":"Administration of recombinant human IL11 after supralethal radiation exposure promotes survival in mice: interactive effect with thrombopoietin","volume":"157","author":"A Van der Meeren","year":"2002","journal-title":"Radiat Res"},{"issue":"18","key":"ref26","first-page":"4947","article-title":"Increased survival and multilineage hematopoietic protection from delayed and severe myelosuppressive effects of a nitrosourea with recombinant interleukin-11","volume":"54","author":"R Maze","year":"1994","journal-title":"Cancer Res"},{"issue":"6","key":"ref27","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood.V83.6.1499.bloodjournal8361499","article-title":"Recombinant human interleukin-11 stimulates multilineage hematopoietic recovery in mice after a myelosuppressive regimen of sublethal irradiation and carboplatin","volume":"83","author":"JP Leonard","year":"1994","journal-title":"Blood"},{"issue":"4","key":"ref28","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1084\/jem.178.4.1175","article-title":"Progenitor cell hyperplasia with rare development of myeloid leukemia in interleukin 11 bone marrow chimeras","volume":"178","author":"RG Hawley","year":"1993","journal-title":"J Exp Med"},{"issue":"4","key":"ref29","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1182\/blood.V81.4.965.965","article-title":"In vivo effects of recombinant interleukin-11 on myelopoiesis in mice","volume":"81","author":"G Hangoc","year":"1993","journal-title":"Blood"},{"issue":"1","key":"ref30","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1182\/blood.V81.1.27.27","article-title":"Effects of recombinant human interleukin-11 on hematopoietic reconstitution in transplant mice: acceleration of recovery of peripheral blood neutrophils and platelets","volume":"81","author":"XX Du","year":"1993","journal-title":"Blood"},{"issue":"3","key":"ref31","first-page":"295","article-title":"Interleukin-11 expression in donor bone marrow cells improves hematological reconstitution in lethally irradiated recipient mice","volume":"22","author":"SR Paul","year":"1994","journal-title":"Exp Hematol"},{"issue":"5","key":"ref32","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1002\/stem.140517","article-title":"Thrombopoietic activity of recombinant human interleukin 11 (rHuIL-11) in normal and myelosuppressed nonhuman primates","volume":"14","author":"FJ Schlerman","year":"1996","journal-title":"Stem Cells"},{"issue":"2","key":"ref33","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1667\/RR3202","article-title":"Effects of recombinant human interleukin 11 on thrombocytopenia and neutropenia in irradiated rhesus monkeys","volume":"162","author":"J Hao","year":"2004","journal-title":"Radiat Res"},{"issue":"3","key":"ref34","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.exphem.2010.12.008","article-title":"Functional characterization of hematopoietic stem cells in the spleen","volume":"39","author":"Y Morita","year":"2011","journal-title":"Exp Hematol"},{"issue":"9","key":"ref35","doi-asserted-by":"crossref","first-page":"1145","DOI":"10.1515\/hsz-2013-0166","article-title":"Interleukin-6 and interleukin-11: same same but different","volume":"394","author":"C Garbers","year":"2013","journal-title":"Biol Chem"},{"issue":"Pt 9","key":"ref36","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1107\/S1399004714012267","article-title":"The structure of human interleukin-11 reveals receptor-binding site features and structural differences from interleukin-6","volume":"70","author":"TL Putoczki","year":"2014","journal-title":"Acta Crystallogr D Biol Crystallogr"},{"issue":"2","key":"ref37","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1038\/nbt0297-142","article-title":"I. A bioactive designer cytokine for human hematopoietic progenitor cell expansion","volume":"15","author":"M Fischer","year":"1997","journal-title":"Nat Biotechnol"},{"key":"ref38","author":"J Birkmann","year":"1999"},{"issue":"6","key":"ref39","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1634\/stemcells.18-6-444","article-title":"Signal through gp130 activated by soluble interleukin (IL)-6 receptor (R) and IL-6 or IL-6R\/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors","volume":"18","author":"T Kimura","year":"2000","journal-title":"Stem Cells"},{"issue":"13","key":"ref40","doi-asserted-by":"crossref","first-page":"1979","DOI":"10.1096\/fj.99-0913com","article-title":"Liver regeneration induced by a designer human IL-6\/sIL-6R fusion protein reverses severe hepatocellular injury","volume":"14","author":"E Galun","year":"2000","journal-title":"FASEB J"},{"issue":"7","key":"ref41","doi-asserted-by":"crossref","first-page":"3575","DOI":"10.4049\/jimmunol.161.7.3575","article-title":"In vivo and in vitro activities of the gp130-stimulating designer cytokine Hyper-IL-6","volume":"161","author":"M Peters","year":"1998","journal-title":"J Immunol"},{"issue":"3","key":"ref42","doi-asserted-by":"crossref","first-page":"1257","DOI":"10.1074\/jbc.274.3.1257","article-title":"The designer cytokine hyper-interleukin-6 is a potent activator of STAT3-dependent gene transcription in vivo and in vitro","volume":"274","author":"T Rakemann","year":"1999","journal-title":"J Biol Chem"},{"issue":"2","key":"ref43","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1080\/019262301317052521","article-title":"Protective effect of rhIL-11 in a murine model of acetaminophen-induced hepatotoxicity","volume":"29","author":"WL Trepicchio","year":"2001","journal-title":"Toxicol Pathol"},{"issue":"7","key":"ref44","doi-asserted-by":"crossref","first-page":"4229","DOI":"10.4049\/jimmunol.0900622","article-title":"IL-11 regulates autoimmune demyelination","volume":"183","author":"BT Gurfein","year":"2009","journal-title":"J Immunol"},{"issue":"3","key":"ref45","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1038\/nm0398-303","article-title":"Infertility in female mice lacking the receptor for interleukin 11 is due to a defective uterine response to implantation","volume":"4","author":"L Robb","year":"1998","journal-title":"Nat Med"},{"issue":"5","key":"ref46","doi-asserted-by":"crossref","first-page":"684","DOI":"10.1161\/CIRCULATIONAHA.109.893677","article-title":"Therapeutic activation of signal transducer and activator of transcription 3 by interleukin-11 ameliorates cardiac fibrosis after myocardial infarction","volume":"121","author":"M Obana","year":"2010","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0154520","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,17]],"date-time":"2023-08-17T22:21:31Z","timestamp":1692310891000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0154520"}},"subtitle":[],"editor":[{"given":"Kevin D","family":"Bunting","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2016,5,4]]},"references-count":46,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2016,5,4]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0154520","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,5,4]]}}}